Knowledge Management System of Hefei Institute of Physical Science,CAS
Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer | |
Xu, Yi-Bing1,2; Zhang, Yiping1,2; Song, Zhengbo1,2; Wang, Wenxian1,2; Shao, Lan1,2 | |
2021 | |
发表期刊 | CANCER MANAGEMENT AND RESEARCH |
ISSN | 1179-1322 |
通讯作者 | Shao, Lan(shaolan1677@163.com) |
摘要 | Background: Brain metastasis (BM) is an important factor shortening the lives of patients with lung cancer. Patients with cystic BM have seldom been reported. Here, we compared the efficacy and prognosis of different therapeutic schedules for solid BM and cystic BM in patients with non-small cell lung cancer (NSCLC). Methods: A retrospective study was conducted of 355 patients with pathologically confirmed stage IV NSCLC, all of whom had BM. We analyzed the clinical characteristics of these patients and the efficacy of targeted drugs and chemotherapy regimens. Results: A total of 255 patients with solid BM (cohort 1) and 33 patients with cystic BM (cohort 2) had evaluable efficacy. We evaluated these 33 patients in cohort 2. The median progression-free survival (PFS) and overall survival (OS) were 8.4 months and 23.0 months, respectively. A significant difference was observed between targeted regimens and chemotherapy treatment in terms of the PFS (12.6 months vs 6.3 months, P = 0.001) and OS (47.9 months vs 17.0 months, P = 0.007). Multivariate analyses showed that treatment regimen (chemotherapy) was a poor prognostic factor for PFS (P < 0.05). Cystic BM may be more likely to occur in patients with NSCLC with genetic mutations. A difference in prognosis was observed between patients who underwent targeted treatment and chemotherapy. A significant difference in intracranial PFS was observed between cohorts (cohort 1 vs cohort 2: 15.4 months vs 9.9 months, P = 0.015), and this advantage was clear in patients who did not receive targeted therapies (11.7 months vs 6.5 months, P = 0.003). However, the OS in patients with targeted therapies in cohort 2 was significantly longer than that in cohort 1 (23.4 months vs 47.9 months, P = 0.013). Conclusion: Patients with NSCLC, particularly those who develop cystic BM, should be genetically tested as much as possible to find out more suitable drug therapies. |
关键词 | cystic brain metastases tyrosine kinase inhibitors chemotherapy radiation therapy lung cancer |
DOI | 10.2147/CMAR.S314060 |
关键词[WOS] | RADIOSURGERY ; TUMORS ; TRIAL |
收录类别 | SCI |
语种 | 英语 |
资助项目 | Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission[2019RC027] |
项目资助者 | Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission |
WOS研究方向 | Oncology |
WOS类目 | Oncology |
WOS记录号 | WOS:000684201000004 |
出版者 | DOVE MEDICAL PRESS LTD |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/124331 |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Shao, Lan |
作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou 310022, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou 310022, Peoples R China |
推荐引用方式 GB/T 7714 | Xu, Yi-Bing,Zhang, Yiping,Song, Zhengbo,et al. Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer[J]. CANCER MANAGEMENT AND RESEARCH,2021,13. |
APA | Xu, Yi-Bing,Zhang, Yiping,Song, Zhengbo,Wang, Wenxian,&Shao, Lan.(2021).Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer.CANCER MANAGEMENT AND RESEARCH,13. |
MLA | Xu, Yi-Bing,et al."Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer".CANCER MANAGEMENT AND RESEARCH 13(2021). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论